ECG patches and glucose monitors

Wearable sleep monitors and posture belts

These devices can be used for both exploratory and primary endpoints, and may or may not be regulated as medical devices depending on their function and use in the trial.

FDA’s Key Regulatory Principles for DHT Use

FDA guidance outlines five foundational expectations for using DHTs:

• Fit-for-purpose selection: The DHT must be suitable for its intended clinical use and patient population
• Verification and validation: Both analytical and clinical validation are required
• Data handling and integrity: Sponsors must ensure secure, auditable, and GCP-compliant data capture
• Participant engagement: Usability, burden minimization, and training are essential
• Transparency in submissions: All relevant information must be included in the IND/NDA/BLA

These expectations apply regardless of whether the DHT is part of a decentralized, hybrid, or traditional site-based trial.

Validation Requirements for Digital Endpoint Devices

One of the most critical aspects of FDA compliance is demonstrating that the DHT is validated for its intended use:

• Analytical Validation: Accuracy, precision, range, and repeatability of measurements under controlled conditions
• Clinical Validation: Evidence that the digital measure is clinically meaningful and reflects the disease construct
• Usability Validation: Studies confirming participants can use the device correctly with minimal training

For example, a wrist-worn device for detecting sleep quality must show correlation with polysomnography and demonstrate reproducibility in the target population.

Risk-Based Assessment and Classification

The FDA encourages a risk-based approach when evaluating DHTs. Key factors include:

• Device invasiveness: Passive sensors vs active wearable patches
• Data criticality: Primary endpoint vs exploratory digital marker
• Use duration: One-time use vs continuous monitoring over months
• Signal reliability: Potential for false positives/negatives

Tools that directly impact patient safety or treatment decisions undergo closer scrutiny and may require premarket clearance if used outside their labeled indications.

IND and NDA/BLA Submission Considerations

Sponsors must clearly outline DHT-related content in their submission packages, including:

• Device name, version, manufacturer, regulatory status
• Validation reports (analytical, clinical, usability)
• DHT deployment plan: how, when, and where the device will be used
• Training materials and patient support protocols
• Data flow diagrams and system architecture
• eSource considerations and audit trail documentation

Early engagement with the agency (e.g., through Type B or pre-IND meetings) is encouraged.

21 CFR Part 11 and Data Integrity for Wearables

Data collected from wearables and apps is considered eSource and must meet Part 11 compliance:

• Access Control: Passwords, biometric verification, or token-based login
• Audit Trails: All entries, edits, and deletions must be time-stamped
• Electronic Signatures: Verified and attributed to a specific user
• System Validation: Documented evidence of intended performance under real-use conditions

Many CROs partner with cloud vendors to maintain GxP-compliant pipelines with certified data centers. For example, PharmaSOP provides templates for DHT compliance under Part 11.

FDA Digital Health Pilot Programs and Resources

Sponsors are encouraged to leverage FDA pilot initiatives like:

• Digital Health Center of Excellence (DHCoE): Provides DHT guidance and policy updates
• SaMD Pre-Cert Program: For software-based tools used in diagnostics or therapeutics
• CDRH’s eSource Guidance: On using digital health data directly in clinical submissions

Visit FDA’s DHCoE for more resources.

Case Study: Wearable Use in a Parkinson’s Digital Biomarker Trial

A sponsor used wrist accelerometers and ePROs to detect bradykinesia in Parkinson’s patients. FDA feedback emphasized:

• Need for correlation with UPDRS scores across severity levels
• Validation of motion-derived endpoints against blinded rater assessment
• Documentation of device re-calibration intervals
• Patient training videos and comprehension assessments

The sponsor’s NDA was accepted with full DHT module and referenced peer-reviewed publications on digital phenotyping.

Conclusion: Building FDA-Ready Digital Trials

The FDA’s guidance is not meant to stifle innovation—but to ensure digital technologies meet the same rigor expected of any clinical trial measure. Sponsors and CROs must proactively address data validity, patient usability, and compliance to ensure acceptance of digital endpoints.

As DHTs become mainstream, those who build quality into design and submit clear, validated evidence will gain a regulatory advantage and improve patient-centric outcomes.